PEDIACARE CHILDREN'S ALLERGY OTC
Generic Name and Formulations:
Diphenhydramine HCl 12.5mg; per 5mL; liq; cherry-flavor, alcohol-free, contains sodium 14mg/5mL.
McNeil Consumer Healthcare
Indications for PEDIACARE CHILDREN'S ALLERGY:
Rhinorrhea, sneezing, allergy symptoms.
<4yrs: do not use. 4–5yrs: not recommended. 6–11yrs: 5mL every 4 hours; max 6 doses/24 hours.
Children <4yrs old. Concomitant other diphenhydramine products (including topicals). For use as a sedative hypnotic.
Glaucoma. GI or GU obstruction. Asthma. Lower respiratory disorders.
See Contraindications. Increased CNS effects with other CNS depressants.
Drowsiness, anticholinergic effects, excitability.
Liq—4oz (w. dosing cup)
Clinical Pain Advisor Articles
- Chronic Neuropathic Pain Updated Classification by IASP for ICD-11
- Buprenorphine-Naloxone Found to Be More Cost-Effective Than Extended-Release Naltrexone
- Ultrasound-Guided C2 Coblation May Be Effective for Cervicogenic Headache
- Meta-Analysis of Opioid Treatment for Chronic Noncancer Pain
- Opioids Found to Increase Risk for Community-Acquired Pneumonia, Particularly in HIV
- Reviewing the Use of Buprenorphine in Perioperative Pain Management
- Early Physical Therapy for Musculoskeletal Pain May Reduce Opioid Use
- External Trigeminal Nerve Stimulation May Alleviate Migraine Pain
- IASP Updates Diagnosis Criteria for Chronic Primary Pain for ICD-11
- Galcanezumab Provides Persistent Preventive Effects in Episodic, Chronic Migraine
- Comparable Analgesia With Low-Dose IV Ketamine, Morphine for Acute Pain
- Benzodiazepines, if Prescribed, May Not Affect Methadone Treatment Retention
- When Opioid Prescribing Guidelines Become Rules
- IV Fluid Confers No Significant Treatment Effect on Migraine Pain
- American Headache Society Releases Position Statement on Novel Preventive and Acute Migraine Treatments